Table 2 The clinical characteristics of patients with early (PFS ≤18 months) or late (PFS >18 months) progression
|  | All patients (N = 36) | PFS ≤ 18 months (N = 18) | PFS > 18 months (N = 18) | Pvalue |
|---|---|---|---|---|
Age (years, mean(SD)) | 61.3(8.3) | 61.9 ± 7.8 | 60.6 ± 8.7 | 0.633 |
Male, n (%) | 21(58.3%) | 10(55.6%) | 11(61.1%) | 1.000 |
M protein | Â | Â | Â | 0.210 |
IgG, n (%) | 19(52.8%) | 7(38.9%) | 12(66.6%) | Â |
IgA, n (%) | 10(27.8%) | 7(38.9%) | 3(16.7%) | Â |
Light chain, n (%) | 7(19.4%) | 4(22.2%) | 3(16.7%) | Â |
International staging system | Â | Â | Â | 0.881 |
Stage 1, n (%) | 5(13.9%) | 2(11.1%) | 3(16.7%) | Â |
Stage 2, n (%) | 12(33.3%) | 6(33.3%) | 6(33.3%) | Â |
Stage 3, n (%) | 19(52.8%) | 10(55.6%) | 9(50%) | Â |
Durie-Salmon stage | Â | Â | Â | 1.000 |
Stage 1, n (%) | 0 | 0 | 0 | Â |
Stage 2, n (%) | 5(13.9%) | 2(11.1%) | 3(16.7%) | Â |
Stage 3, n (%) | 31(86.1%) | 16(88.9%) | 15(83.3%) | Â |
Percentage of plasma cell in bone marrow (%, mean (SD)) | 50.8 ± 25.3 | 54.3 ± 26.8 | 47.3 ± 23.8 | 0.740 |
Anemia, n (%) | 27(75%) | 14(77.8%) | 13(72.2%) | 1.000 |
Renal insufficiency, n (%) | 9(25%) | 5(27.8%) | 4(22.2%) | 1.000 |
Hypercalcemia, n (%) | 14(38.9%) | 8(44.4%) | 6(33.3%) | 0.733 |
Bone disease, n (%) | 25(69.4%) | 14(77.8%) | 11(61.1%) | 0.471 |
Cytogenetic abnormality, n (%) | 7(19.4%) | 3(16.7%) | 4(22.2%) | 1.000 |
Bortezomib-containing induction Tx, n (%) | 11(30.6%) | 4(22.2%) | 7(38.9%) | 0.471 |
Auto-HSCT in 1st fine Tx, n (%) | 9(25%) | 2(11.1%) | 7(38.9%) | 0.121 |
Treatment response: | Â | Â | Â | Â |
CR, n (%) | 7(19.4%) | 1(5.6%) | 6(33.3%) | 0.088 |
VGPR, n (%) | 26(72.2%) | 14(77.8%) | 12(66.7%) | 0.711 |
PR, n (%) | 3(8.3%) | 3(16.7%) | 0 | 0.229 |
Expression of MALAT1 at diagnosis (Mean ΔCT ± SD) |  | -5.52 ± 1.15 | -5.77 ± 0.89 | 0.353 |
Magnitude of MALAT1 change after treatment (Difference in ΔCT) |  | 1.26 ± 1.06 | 2.09 ± 0.79 | 0.011 |